CHRS COHERUS ONCOLOGY INC revenue, earnings and financials
For the quarter ended June 30, 2026, COHERUS ONCOLOGY INC reported revenue of $14.3M (up 39.5% from a year earlier), net income of −$20.6M and diluted EPS of −$0.13; over the last four quarters revenue was $50.9M and net income −$132M; for the fiscal year ended December 2025 revenue was $42.2M, up 59.8% on the year before.
CHRS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $42.2M, gross profit n/a, operating income −$181M, net income $168M (margin 398.4%), EPS $1.43
- Fiscal year ended Dec 2024: revenue $26.4M, gross profit n/a, operating income −$200M, net income $28.5M (margin 108.0%), EPS $0.25
- Fiscal year ended Dec 2023: revenue $1.22M, gross profit n/a, operating income −$216M, net income −$238M (margin -19531.4%), EPS −$2.53
- Fiscal year ended Dec 2022: revenue $211M, gross profit n/a, operating income −$257M, net income −$292M (margin -138.2%), EPS −$3.76
- Fiscal year ended Dec 2021: revenue $327M, gross profit n/a, operating income −$264M, net income −$287M (margin -87.9%), EPS −$3.81
CHRS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $14.3M (up 39.5% year over year), net income −$20.6M, EPS −$0.13
- Quarter ended Mar 31, 2026: revenue $12.3M (up 62.0% year over year), net income −$38.3M, EPS −$0.28
- Quarter ended Dec 31, 2025 (from the annual report): revenue $12.7M (up 64.9% year over year), net income −$37.6M, EPS −$3.40
- Quarter ended Sep 30, 2025: revenue $11.6M (up 91.2% year over year), net income −$35.5M, EPS −$0.31
- Quarter ended Jun 30, 2025: revenue $10.3M (down 0.4% year over year), net income $298M, EPS $2.57
- Quarter ended Mar 31, 2025: revenue $7.60M (up 229.2% year over year), net income −$56.6M, EPS $2.57
- Quarter ended Dec 31, 2024 (from the annual report): revenue $7.73M (up 104.7% year over year), net income −$50.7M, EPS −$0.46
- Quarter ended Sep 30, 2024: revenue $6.05M (down 91.9% year over year), net income −$10.8M, EPS −$0.09
- Quarter ended Jun 30, 2024: revenue $10.3M (down 82.5% year over year), net income −$12.9M, EPS −$0.11
- Quarter ended Mar 31, 2024: revenue $2.31M (down 92.9% year over year), net income $103M, EPS $0.91
- Quarter ended Dec 31, 2023 (from the annual report): revenue −$165M (down 462.7% year over year), net income −$79.7M, EPS −$0.67
- Quarter ended Sep 30, 2023: revenue $74.6M (up 64.2% year over year), net income −$39.6M, EPS −$0.41
- Quarter ended Jun 30, 2023: revenue $58.7M (down 2.4% year over year), net income −$42.9M, EPS −$0.49
- Quarter ended Mar 31, 2023: revenue $32.4M (down 46.0% year over year), net income −$75.7M, EPS −$0.96
- Quarter ended Dec 31, 2022 (from the annual report): revenue $45.4M (down 38.2% year over year), net income −$58.9M, EPS −$0.76
- Quarter ended Sep 30, 2022: revenue $45.4M (down 44.9% year over year), net income −$86.7M, EPS −$1.11
- Quarter ended Jun 30, 2022: revenue $60.2M (down 31.4% year over year), net income −$50.2M, EPS −$0.65
- Quarter ended Mar 31, 2022: revenue $60.1M (down 27.6% year over year), net income −$96.1M, EPS −$1.24
- Quarter ended Dec 31, 2021 (from the annual report): revenue $73.4M, net income −$45.7M, EPS −$0.55
- Quarter ended Sep 30, 2021: revenue $82.5M, net income −$38.5M, EPS −$0.49
CHRS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$139M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$20.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$175M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$241M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$37.4M, share buybacks n/a
CHRS balance sheet
- Jun 30, 2026: cash $82.9M, total assets $191M, total liabilities $130M, shareholders' equity $60.8M
- Mar 31, 2026: cash $115M, total assets $266M, total liabilities $187M, shareholders' equity $78.6M
- Dec 31, 2025: cash $88.9M, total assets $258M, total liabilities $197M, shareholders' equity $61.0M
- Sep 30, 2025: cash $103M, total assets $517M, total liabilities $429M, shareholders' equity $87.8M
- Jun 30, 2025: cash $217M, total assets $439M, total liabilities $320M, shareholders' equity $120M
- Mar 31, 2025: cash $82.4M, total assets $371M, total liabilities $555M, shareholders' equity −$183M
- Dec 31, 2024: cash $126M, total assets $449M, total liabilities $581M, shareholders' equity −$132M
- Sep 30, 2024: cash $97.7M, total assets $505M, total liabilities $593M, shareholders' equity −$88.0M
What is CHRS's revenue?
COHERUS ONCOLOGY INC reported $50.9M of revenue over its last four quarters, through June 30, 2026.
Is CHRS profitable?
No. COHERUS ONCOLOGY INC lost $132M over the last four quarters.
What is CHRS's EPS?
Diluted earnings per share over the last four quarters were −$4.12; −$0.13 in the latest quarter.